However, the association of the KRAS-variant with altered miRNA signatures has been found in every tumor in which it has been analyzed, including lung cancer[21], melanoma[10], head and neck cancer[30] and triple negative breast cancer[23]. This evidence concerns the gene KRAS and lung carcinoma.